Trial Search Results

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

The purpose of this study is to determine the effect of the study drug, MPDL3280A (a monoclonal antibody) on programmed cell death-1 ligand 1 (PD-L1)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The study also aims to learn more about the safety and tolerability of the study drug.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Genentech, Inc.


  • Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody


Phase 2


Inclusion Criteria:

   - Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent

   - PDL1-positive status as determined by an immunohistochemistry assay performed by a
   central laboratory. A positive result in chemotherapy, chemoradiation of the tumor
   sample biopsy will satisfy the eligibility criterion

   - Eastern Cooperative Oncology group Performance Status of 0 or 1

   - Life expectancy greater than or equal to 12 weeks

   - Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version

   - Adequate hematologic and end organ function

Exclusion Criteria:

   - Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3
   weeks prior to initiation of study treatment; the following exceptions are allowed.
   Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors
   approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day

   - Treatment with any other investigational agent or participation in another clinical
   trial with therapeutic intent within 28 days prior to enrollment

   - Known central nervous system disease, including treated brain metastases in the
   following participants:

      1. who will not receive prior chemotherapy for advanced disease

      2. who progress during or following a prior-platinum based chemotherapy regimen for
      advanced disease (referred as 2L+ participants)

   - Participants with a history of treated asymptomatic brain metastases are allowed in
   the 2L+ participants and previously treated for brain metastases.

   - Leptomeningeal disease

   - Uncontrolled tumor-related pain

   - Uncontrolled hypercalcemia

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting